BUI vs LDP
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
The Advanced Deterministic Scorecard reveals severe financial health concerns with a Piotroski F-Score of just 1/9, indicating weak fundamental strength. Despite a low P/E of 6.22 compared to the sector average of 30.89 and a high dividend yield of 6.14%, profitability metrics are entirely absent (0.00% margins), and critical financial data is missing, raising transparency issues. The technical trend is deeply bearish at 10/100, and insider sentiment is weak at 40/100, further undermining confidence. While historical price performance shows strong 3Y and 5Y gains, the lack of financial disclosures and extremely poor health metrics suggest elevated risk.
LDP exhibits severe fundamental weakness according to deterministic metrics, highlighted by a critical Piotroski F-Score of 1/9. The current market price of $20.73 represents a significant premium over the calculated intrinsic value of $15.47, suggesting the asset is overvalued. While the dividend yield remains a strong attractor at 7.58%, the combination of a bearish technical trend (0/100) and poor health scores outweighs the income potential. Overall, the fund shows signs of fundamental deterioration despite historical price appreciation.
Compare Another Pair
Related Comparisons
BUI vs LDP: Head-to-Head Comparison
This page compares BlackRock Utilities, Infrastructure & Power Opportunities Trust (BUI) and Cohen & Steers Limited Duration Preferred and Income Fund, Inc. (LDP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.